Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 1, 2013, Pages 131-138

  De Vos, Lisanne C ^a   Noordzij, Marjon J ^a   Mulder, Douwe J ^a   Smit, Andries J ^a   Lutgers, Helen L ^b   Dullaart, Robin P F ^b   Kamphuisen, Pieter W ^a   Zeebregts, Clark J ^c   Lefrandt, Joop D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Division of Endocrinology   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

advanced glycation end products; atherosclerosis; oxidative stress; peripheral vascular disease; skin autofluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ABDOMINAL AORTA ANEURYSM; ADULT; AGE; AGED; ARTICLE; AUTOFLUORESCENCE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GEOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SKIN AUTOFLUORESCENCE; SMOKING;

AGE FACTORS; AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COMORBIDITY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; OPTICAL IMAGING; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SKIN; SKIN ABSORPTION; SMOKING; SPECTROMETRY, FLUORESCENCE; UP-REGULATION;

EID: 84871735365     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300016     Document Type: Article

References (26)

1. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
2. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
3. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, Howard BV. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109:733-739.
4. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol. 1995;147:654-667.
5. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025-1031.
6. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Thorpe SM, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004;53:1813-1823.
7. Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care. 2007;30:670-676.
8. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324-1330.
9. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3687-3693.
10. Koetsier M, Nur E, Chunmao H, Lutgers HL, Links TP, Smit AJ, Rakhorst G, Graaff R. Skin color independent assessment of aging using skin autofluorescence. Opt Express. 2010;18:14416-14429.
11. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diab Care. 2007;30:107-112.
12. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009;52:789-797.
13. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34:S62-S69.
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
16. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
17. Noordzij MJ, Lefrandt JD, Loeffen EA, Saleem BR, Meerwaldt R, Lutgers HL, Smit AJ, Zeebregts CJ. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging. 2012;28:431-438.
18. Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J. 2009;17:162-168.
19. Shiotsu Y, Mori Y, Hatta T, Maki N, Iida K, Matsuoka E, Kado H, Ishida R, Kishimoto N, Tamagaki K, Nishimura M, Iwamoto N, Ono T, Matsubara H, Kosaki A. Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease. Nephron Extra. 2011;1:242-250.
20. Takahashi R, Imamura A, Yoshikane M, Suzuki M, Murakami R, Cheng XW, Numaguchi Y, Ikeda N, Murohara T, Okumura K. High serum concentrations of pentosidine, an advanced glycation end product, are associated with low normal value of ankle-brachial index in apparently healthy men. Metab Clin Exp. 2011;60:649-654.
21. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271.
22. Hricik DE, Wu YC, Schulak A, Friedlander MA. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transplant. 1996;10:568-573.
23. Dorrian CA, Cathcart S, Clausen J, Shapiro D, Dominiczak MH. Factors in human serum interfere with the measurement of advanced glycation endproducts. Cell Mol Biol (Noisy-le-grand). 1998;44:1069-1079.
24. Conway B, Edmundowicz D, Matter N, Maynard J, Orchard T. Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol Ther. 2010;12:339-345.
25. Hofmann B, Adam AC, Jacobs K, Riemer M, Erbs C, Bushnaq H, Simm A, Silber RE, Santos AN. Advanced glycation end product associated skin autofluorescence: a mirror of vascular function? Exp Gerontol. May 12, 2012. http://dx.doi.org/ 10.1016/j.exger.2012.04.011. http://www. sciencedirect.com/science/article/pii/ S0531556512001179. Accessed November 13, 2012.
26. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs. 2008;17:983-996.